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Abstract
Background
The relationship between chronic obstructive pulmonary disease (COPD) and periproce-
dural complications of percutaneous coronary interventions (PCIs) is influenced by several
factors. We aimed to investigate the association between COPD, its complication type and
rate in patients undergoing PCI.
Methods
Data were prospectively collected using the Polish Cardiovascular Intervention Society
national registry (ORPKI) on all PCIs performed in Poland between January 2015 and
December 2016. COPD was present in 5,594 of the 221,187 patients undergoing PCI. We
assessed the frequency and predictors of periprocedural complications in PCI.
Results
Patients with COPD were elder individuals (70.3 ± 9.9 vs. 67 ± 10.8 years; p < 0.05). We
noted 145 (2.6%) periprocedural complications in the COPD group and 4,121 (1.9%) in the
non-COPD group (p < 0.001). The higher incidence of periprocedural complications in the
COPD patients was mainly attributed to cardiac arrest (p = 0.001), myocardial infarctions
(p = 0.002) and no-reflows (p < 0.001). COPD was not an independent predictor of all peri-
procedural complications. On the other hand, COPD was found to be an independent pre-
dictor of increased no-reflow risk (odds ratio [OR] 1.447, 95% CI 1.085–1.929; p = 0.01),
and at the same time, of decreased risk of periprocedural allergic reactions (OR 0.117, 95%
CI 0.016–0.837; p = 0.03).
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Conclusions
In conclusion, periprocedural complications of PCIs are more frequent in patients with
COPD. COPD is an independent positive predictor of no-reflow and a negative predictor of
periprocedural allergic reactions.
Introduction
The prevalence of chronic obstructive pulmonary disease (COPD) in the general population is
estimated at 7.6% [1]. Diagnosis of COPD increases the risk of cardiovascular diseases and
resulting mortality [2]. 2.4–10% of patients undergoing percutaneous coronary intervention
(PCI) have been diagnosed with COPD [3,4]. More importantly, it has been observed that
patients with COPD treated with PCI have more comorbidities and a greater extent of coro-
nary artery disease. In addition, COPD is associated with an increased risk of repeated revascu-
larization after PCI [5]. Data availability on the incidence of periprocedural complications in
patients undergoing PCIs is limited. It has been demonstrated that the incidence of periproce-
dural complications in patients undergoing PCIs has decreased in previous years and is esti-
mated at 1–3%. However, other studies have shown higher frequencies [6]. Several predictors
of periprocedural complications, including advanced age, coronary plaque burden, chronic
total occlusions (CTOs), coronary artery tortuosity, gender, PCI overall volume at one center
and daily PCI volume have been demonstrated [7,8]. There are limited and conflicting data
regarding periprocedural complications of PCI in patients with COPD. Some publications
demonstrated that the overall complication rate was significantly lower in those with COPD.
Whereas, patients with COPD had significantly higher incidences of death, major entry site
complications and longer length of hospital stay [5].
The aim of this study was to assess the relationship between COPD, periprocedural compli-
cations and their predictors in patients treated with PCI.
Materials and methods
Study population, design and definitions
We analyzed prospectively collected national data from all patients who underwent PCIs in
Poland between January 2015 and December 2016. Data on PCI practice in Poland were
obtained from the ORPKI Polish National dataset which is coordinated nationwide by Jagiello-
nian University Medical College in cooperation with AISN PTK (Association of Cardiovascu-
lar Interventions–The Polish Cardiac Society). The method of collecting data in the ORPKI
registry was presented in previously published works [9,10]. Consecutive patients with COPD
were included. COPD was defined on the basis of previously established diagnosis. This fact
was taken into account on the basis of existing medical records, including discharge cards and
the typical treatment used for COPD. All indices recorded in the ORPKI database are based on
periprocedural data uploaded by the operator after each procedure. Therefore, they do not
include all in-hospital complications, mainly those which occurred after the procedure until
discharge from the hospital. Also, we did not collect follow-up data after discharge. The diag-
nosis of all other periprocedural complications including death, cardiac arrest, puncture site
bleeding, no-reflow, cerebral stroke, coronary artery perforation (CAP), coronary artery dis-
section, allergic reactions ultimately depended on the operators’ decisions. Periprocedural
major adverse cardiac events (MACCE) were defined as the combination of all-cause deaths,
COPD and periprocedural complications in patients treated with PCI
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myocardial infarction (MI) and cerebral stroke. The thrombolysis in myocardial infarction
(TIMI) grade flow was used to estimate procedural angiographic effectiveness. PCI was consid-
ered effective when TIMI grade 3 was obtained after the procedure. The overall complication
rate was presented as the number of patients with defined periprocedural complications, even
if the particular patient presented more than one complication.
Statistical analysis
All continuous variables were evaluated with the Kolmogorov-Smirnov test for distribution.
Continuous variables are presented as mean ± standard deviation and median ± interquartile
range. Categorical variables are presented as numeric values and percentages. Continuous var-
iables were compared using the two-tailed Student’s t-test and the Mann-Whitney U-test,
whereas categorical variables via the χ2 test. ANOVA was used to compare data between fol-
lowing years. To identify predictors of all periprocedural complications and those more spe-
cific such as allergic reactions and no-reflow phenomenon in the overall group of patients
undergoing PCI, univariate and multivariate analyses were performed. Both, univariate and
multivariate regression models for MACCE were constructed. A model based on the retro-
grade correction method was created. In this analysis, the following variables were tested: age,
gender, diabetes, previous cerebral stroke, MI, PCI, coronary artery by-pass grafting (CABG),
smoking status, psoriasis, kidney disease, COPD, vascular access, fractional flow reserve, intra-
vascular ultrasound, optical coherence tomography, thrombectomy, rotablation (RA), phar-
macological treatment, baseline TIMI flow, contrast and radiation dose, gender, clinical
presentation of coronary artery disease (CAD), type of coronary artery lesions including distri-
bution, bifurcations and chronic total occlusion (CTO) procedures. A p value lower than 0.05
was considered to be significant. The statistical analyses were performed using Statistica 10.0
software (Dell Software, Inc, Round Rock, TX, USA).
Results
We analyzed 221,187 PCIs performed in Poland between January 2015 and December 2016.
Among all PCI patients, 5,594 had COPD (2.5%). We found 145 overall periprocedural com-
plications in 5,594 patients with COPD (2.6%) and 4,121 in 215,593 patients from the non-
COPD group (1.9%) (p< 0.001) (Fig 1). It was mostly determined by the greater percentage of
cardiac arrests (1% vs. 0.6%; p = 0.001), MIs (0.2% vs. 0.1%; p = 0.002), and no-reflows (0.9%
vs. 0.5%; p< 0.001) in the COPD group as compared to the non-COPD group (Fig 1). Peri-
procedural allergic reactions were less frequent in the COPD group (0.02% vs. 0.2%;
p = 0.007). Other periprocedural complications did not differ significantly between both
groups (Fig 1).
Periprocedural complications and clinical presentation of CAD
ST-segment elevation MI (STEMI) occurred in 994 patients (17.7%), while non-ST-segment
elevation MI (NSTEMI) took place in 1,384 patients (24.7%). More complications occurred in
STEMI subgroup compared to NSTEMI, which was driven by a higher rate of cardiac arrests
(p = 0.007), deaths (p = 0.02) and no-reflows (p< 0.001) (Table 1). The angiographic success
was significantly lower in STEMI as compared to NSTEMI (p = 0.001). The usage rate of
thrombectomy was higher in the STEMI group (p< 0.001) (Table 1). There were no signifi-
cant differences in vascular access between those two groups. Differences in the location of cul-
prit lesion in STEMI and NSTEMI patients is presented in Table 1. Stable angina (SA)
occurred in 1,549 patients, while acute coronary syndrome (ACS) was noted in 3,980 individu-
als (72%). Among patients from the COPD group, complication rate was higher in patients
COPD and periprocedural complications in patients treated with PCI
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with ACS compared to SA (1.2% vs. 3.1%; p< 0.001), with the most significant contribution
of cardiac arrest (0.6% vs. 1.2%; p = 0.005), death (0% vs. 0.7%; p< 0.001) and no-reflow
(0.5% vs. 1.1%; p = 0.04) (Table 1). This relationship was present despite the fact that PCI of
CTOs (p = 0.01), bifurcations (p = 0.01) and RAs (p< 0.001) were more common in SA
patients. The angiographic success expressed as TIMI grade 3 flow was higher in the SA group
(p< 0.001). Femoral access (FA) was more common in STEMI patients (p = 0.02) (Table 1).
Periprocedural complications and distribution of coronary artery
atherosclerosis
The COPD group consisted of 3,381 patients with single-vessel disease (SVD) (65.6%) and
1,771 individuals with multi-vessel disease (MVD) +/- left main coronary artery (LMCA)
involvement and isolated LMCA disease (34.4%). The rate of MVD patients with LMCA
involvement (p = 0.02), without LMCA involvement (p< 0.001) and isolated LMCA disease
(p< 0.001) was significantly higher in the COPD group compared to the non-COPD group.
Complication rate was almost two times higher in the MVD group compared to the SVD
group (p< 0.001), which was mainly due to higher rate of MACCEs (p< 0.001), dissections
(p = 0.01), cardiac arrests (p< 0.001), deaths (p< 0.001) and no-reflows (p = 0.04) (Table 2).
In the MVD group, there were twice as many PCIs of bifurcations (p< 0.001), many more
Fig 1. The incidence of periprocedural complications in the COPD and non-COPD groups. Data are presented as % unless otherwise indicated. Abbreviations:
AD, arterial dissection; AR, allergic reactions; CA, cardiac arrest; CAP, coronary artery perforation; CS, cerebral stroke; MACCE, major adverse coronary and
cerebrovascular events; MI, myocardial infarction; NS, not significant; PSB, puncture site bleeding.
https://doi.org/10.1371/journal.pone.0204257.g001
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occurrences of LMCA PCIs (p< 0.001), significantly more PCIs of LAD (p< 0.001) and Cx
(p< 0.001), while there were less PCIs of RCA (p< 0.001). We did not confirm any relation-
ship between particular complications and location of the culprit lesion in specific coronary
arteries. In the MVD group, there were significantly more patients with NSTEMI (p< 0.001)
and STEMI (p = 0.02) presentation of CAD, while less with SA (p< 0.001). Differences in vas-
cular access are presented in Table 2.
Gender and periprocedural complications
There were 4,045 males (72.3%) and 1,547 females (27.7%) in the COPD group (Table 3). All
of the complications more frequently occurred in females compared to the males (2.3% vs.
3.3%, p = 0.04). This was mainly due to higher incidence of MI (0.1% vs. 0.4%, p = 0.01),
which occurred despite the fact that more PCIs of bifurcations (p< 0.001) and CTOs
Table 1. Selected indices in COPD group according to clinical presentation of CAD (NSTEMI vs. STEMI) before PCI and SA vs. ACS.
COPD (+), n = 5,594 (100) P-value COPD (+), n = 5,529 (100) P-value
STEMI
n = 994 (17.7)
NSTEMI
n = 1,384 (24.7)
SA
n = 1,549 (28)
ACS
n = 3,980 (72)
Age, years 70.3 ± 10.0
70 [63 78]
71.4 ± 9.6
71 [64 79]
0.006 69.5 ± 8.6
69 [63 76]
70.7 ± 9.5
70 [64 78]
<0.001
All complications 62 (6.2) 38 (2.7) <0.001 19 (1.2) 122 (3.1) <0.001
Arterial dissection 1 (0.1) 3 (0.2) 0.55 0 (0) 5 (0.1) 0.1
CAP 3 (0.3) 3 (0.2) 0.68 4 (0.2) 10 (0.2) 0.9
Cardiac arrest 26 (2.6) 16 (1.1) 0.007 6 (0.6) 48 (1.2) 0.005
Death 17 (1.7) 10 (0.7) 0.02 0 (0) 29 (0.7) <0.001
Allergic reactions 0 (0) 0 (0) - 0 (0) 1 (0.02) 0.5
No-reflow 28 (2.8) 9 (0.6) <0.001 8 (0.5) 43 (1.1) 0.04
Cerebral stroke 0 (0) 0 (0) - 0 (0) 0 (0) -
Puncture site bleeding 4 (0.4) 3 (0.2) 0.4 1 (0.06) 9 (0.2) 0.2
Chronic total occlusion 38 (3.8) 55 (4.0) 0.85 91 (5.9) 171 (4.3) 0.01
Bifurcation 51 (5.1) 91 (6.6) 0.14 122 (7.9) 244 (6.1) 0.01
Rotablation 1 (0.1) 4 (0.3) 0.32 18 (1.2) 11 (0.3) <0.001
Thrombectomy 109 (10.9) 27 (1.2) <0.001 - 141 (3.5) -
TIMI 3 after PCI 841 (88.1) 1,237 (92.2) 0.001 1,438 (92.8) 3,529 (91.8) 0.2
Location of culprit lesion
Left main coronary artery 41 (4.1) 95 (6.9) 0.004 54 (3.5) 206 (5.2) 0.007
Left anterior descending 372 (37.4) 475 (34.3) 0.11 512 (33.0) 1,385 (34.8) 0.2
Circumflex branch 145 (14.6) 379 (27.4) <0.001 391 (25.2) 890 (22.4) 0.02
Intermediate branch 17 (1.7) 20 (1.4) 0.6 25 (1.6) 52 (1.3) 0.38
Right coronary artery 377 (37.9) 380 (27.4) <0.001 483 (31.2) 1,256 (31.5) 0.7
Saphenous vein graft 9 (0.9) 23 (1.7) 0.11 14 (0.9) 54 (1.3) 0.2
Vascular access
Right radial artery 584 (58.7) 820 (59.2) 0.8 941 (60.7) 2,343 (58.9) 0.2
Left radial artery 139 (14.0) 220 (15.9) 0.19 250 (16.1) 611 (15.3) 0.5
Femoral artery 264 (26.5) 344 (24.8) 0.34 340 (21.9) 987 (24.8) 0.02
Others 7 (0.7) 18 (1.3) 0.15 18 (1.2) 39 (1.0) 0.5
Data are presented as % unless otherwise indicated.
Abbreviations: ACS, acute coronary syndrome; CAD, coronary artery disease; CAP, coronary artery perforation; NSTEMI, non-ST segment elevation myocardial
infarction; SA, stable angina; STEMI, ST-segment elevation myocardial infarction; TIMI, thrombolysis in myocardial infarction.
https://doi.org/10.1371/journal.pone.0204257.t001
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(p< 0.001) were performed in males (Table 3). It seems, that the higher prevalence of compli-
cations in women can be mainly owed to the higher STEMI (p< 0.001) and lower SA
(p< 0.001) incidences in individuals before PCI which resulted in the more frequent use of
thrombectomy (p = 0.01) (Table 3).
Table 2. Selected indices in the COPD group according to the distribution of coronary artery atherosclerosis and TIMI flow grade before PCI.
COPD (+), n = 5,152 (100) P-value COPD (+), n = 5,392 (100)
TIMI flow before PCI
P-value
Non-SVD
n = 1,771 (34.4)
SVD
n = 3,381 (65.6)
0–1
n = 1,632 (30.3)
2–3
n = 3,760 (69.7)
Age, years 71.2 ± 9.5
71 [64 77]
69.8 ± 9.2
69 [63 77]
<0.001 70.2 ± 9.9
70 [63 78]
70.4 ± 8.9
70 [64 77]
0.35
All complications 69 (3.9) 68 (2.0) <0.001 76 (4.6) 65 (1.7) <0.001
Arterial dissection 5 (0.3) 1 (0.03) 0.01 3 (0.2) 3 (0.1) 0.37
CAP 3 (0.2) 9 (0.3) 0.49 4 (0.2) 10 (0.3) 0.89
Cardiac arrest 30 (1.7) 21 (0.6) <0.001 34 (2.1) 19 (0.5) <0.001
Death 20 (1.1) 9 (0.3) <0.001 22 (1.3) 7 (0.2) <0.001
Allergic reactions 0 (0) 1 (0.03) 0.46 0 (0) 1 (0.03) 0.51
Myocardial infarction 6 (0.3) 4 (0.1) 0.08 6 (0.3) 6 (0.2) 0.13
No-reflow 24 (1.3) 26 (0.8) 0.04 33 (2.0) 19 (0.5) <0.001
Cerebral stroke 0 (0) 0 (0) - 0 (0) 0 (0) -
Puncture site bleeding 5 (0.3) 5 (0.1) 0.29 3 (0.2) 5 (0.1) 0.65
Chronic total occlusion 86 (4.8) 151 (4.4) 0.52 7 (0.4) 82 (2.2) <0.001
Bifurcation 181 (10.2) 158 (4.7) <0.001 126 (7.7) 239 (6.3) 0.06
Rotablation 9 (0.5) 18 (0.5) 0.9 6 (0.4) 20 (0.5) 0.42
Thrombectomy 56 (3.2) 87 (2.6) 0.22 114 (7.0) 23 (0.6) <0.001
TIMI 3 after PCI 1,599 (92.3) 3,012 (92.4) 0.89 1,327 (81.6) 3,653 (97.4) <0.001
Location of culprit lesion
LMCA 209 (11.8) 6 (0.2) <0.001 53 (3.2) 204 (5.4) <0.001
Left anterior descent 675 (38.1) 1,097 (32.4) <0.001 504 (30.9) 1,334 (35.5) 0.001
Circumflex branch 507 (28.6) 658 (19.5) <0.001 357 (21.9) 903 (24.0) 0.08
Intermediate branch 31 (1.7) 39 (1.1) 0.07 18 (1.1) 55 (1.5) 0.29
Right coronary artery 479 (27.0) 1,187 (35.1) <0.001 578 (35.4) 1,129 (30.0) <0.001
Saphenous vein graft 24 (1.3) 42 (1.2) 0.73 22 (1.3) 46 (1.2) 0.7
Vascular access
Right radial artery 1,023 (57.7) 2,048 (60.6) 0.05 957 (58.6) 2,251 (59.8) 0.39
Left radial artery 266 (15.0) 529 (15.6) 0.55 249 (15.2) 583 (15.5) 0.81
Femoral artery 461 (26.0) 772 (22.8) 0.01 411 (25.2) 886 (23.6) 0.2
Others 21 (1.2) 32 (0.9) 0.4 15 (0.9) 40 (1.1) 0.62
Clinical presentation
Stable angina 370 (20.9) 1,047 (31.0) <0.001 246 (15.1) 1,243 (33.1) <0.001
Unstable angina 522 (29.5) 1,041 (30.8) 0.32 326 (20.0) 1,223 (32.6) <0.001
NSTEMI 547 (30.9) 742 (21.9) <0.001 433 (26.5) 906 (24.1) 0.059
STEMI 310 (17.5) 512 (15.1) 0.02 604 (37.0) 346 (9.2) <0.001
Others 21 (1.2) 37 (1.1) 0.76 22 (1.3) 36 (0.9) 0.2
Data are presented as % unless otherwise indicated.
Abbreviations: CAP, coronary artery perforation; LMCA, left main coronary artery; MVD, multi-vessel disease; NSTEMI, non-ST segment elevation myocardial
infarction; PCI, percutaneous coronary intervention; SVD, single-vessel disease; STEMI, ST-segment elevation myocardial infarction; TIMI, thrombolysis in myocardial
infarction.
https://doi.org/10.1371/journal.pone.0204257.t002
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Vascular access and periprocedural complications
FA was used in 1,344 individuals (24%), while radial access was implemented in 4,250 patients
(76%). A trend towards a higher risk of periprocedural complications in patients with FA was
observed (3.2% vs. 2.4%; p = 0.1). Similarly, when considering each complication separately, there
were no significant differences. However, we have noticed discrepancies in several other features.
Table 3. Selected indices in the COPD group according to gender before PCI.
Variable COPD (+), n = 5,592 (100) P-value
Males
n = 4,045 (72.3)
Females
n = 1,547 (27.7)
Age, years 69.8 ± 9.3
69 [63 77]
71.8 ± 9.1
72 [65 79]
<0.001
All complications 94 (2.3) 51 (3.3) 0.04
Arterial dissection 3 (0.09) 3 (0.2) 0.24
CAP 11 (0.3) 3 (0.2) 0.6
Cardiac arrest 35 (0.9) 20 (1.3) 0.14
Death 19 (0.5) 11 (0.7) 0.26
Allergic reactions 0 (0) 1 (0.06) 0.1
Myocardial infarction 5 (0.1) 7 (0.4) 0.01
No-reflow 36 (0.9) 16 (1.0) 0.61
Cerebral stroke 0 (0) 0 (0) -
Puncture site bleeding 6 (0.1) 4 (0.2) 0.38
Chronic total occlusion 215 (5.3) 52 (3.4) 0.002
Bifurcation 292 (7.2) 77 (5.0) 0.002
Rotablation 22 (0.5) 7 (0.4) 0.67
Thrombectomy 91 (2.2) 52 (3.4) 0.01
TIMI effectiveness (0-2/3) 3,639 (94.0) 1,384 (92.6) 0.9
Location of culprit lesion
Left main coronary artery 203 (5.0) 60 (3.9) 0.7
Left anterior descent 1,389 (34.3) 528 (34.1) 0.88
Circumflex branch 939 (23.2) 355 (22.9) 0.83
Intermediate branch 60 (1.5) 18 (1.2) 0.36
Right coronary artery 1,234 (30.5) 533 (34.4) 0.004
Saphenous vein graft 56 (1.4) 12 (0.7) 0.06
Vascular access
Right radial artery 2,408 (59.5) 913 (59.0) 0.72
Left radial artery 606 (15.0) 263 (17.0) 0.06
Femoral artery 988 (24.4) 356 (23.0) 0.26
Other 43 (1.1) 15 (1.0) 0.75
Clinical presentation
Stable angina 1,176 (29.1) 373 (24.1) <0.001
Unstable angina 1,151 (28.5) 450 (29.1) 0.63
NSTEMI 983 (24.3) 400 (25.9) 0.52
STEMI 686 (17.0) 308 (19.9) 0.009
Others 44 (1.1) 14 (0.9) 0.54
Data are presented as % unless otherwise indicated.
Abbreviations: CAP, coronary artery perforation; NSTEMI, non-ST-segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction;
TIMI, thrombolysis in myocardial infarction.
https://doi.org/10.1371/journal.pone.0204257.t003
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Patients from the FA group were older (71.1 ± 8.9 years vs. 70.1 ± 9.3 years; p< 0.001) and under-
went more PCIs with RA (1.0% vs. 0.3%; p = 0.002). They presented STEMI before PCI more often
(19.6% vs. 10.1%; p = 0.03), while undergoing thrombectomy less often (1.7% vs. 2.8%, p = 0.02).
They also presented SA before PCI less frequently (25.3% vs. 28.5%; p = 0.02). There were no differ-
ences in location of culprit lesion between femoral and radial access subgroups and angiographic
success. No differences were found between PCI of CTOs and bifurcation rate as well.
Pre-PCI TIMI flow and periprocedural complications
Limited blood flow (TIMI 0–1) was found in 1,632 patients (30.3%), while preserved blood
flow was noted in 3,760 individuals (69.7%) before PCI. All complication rates were higher in
the TIMI 0–1 group compared to the TIMI 2–3 group assessed before PCI (p< 0.001). This
was mostly caused by higher percentages of MACCE (p< 0.001), cardiac arrests (p< 0.001),
deaths (p< 0.001) and no-reflows (p< 0.001) (Table 2). The number of patients with STEMI
(p< 0.001) was greater in the group of patients with limited blood flow, whereas there were
fewer patients with SA and UA (p< 0.001). The higher rate of complications in patients with
the TIMI 0–1 grade flow seems to be mostly attributed to the higher rate of STEMI, despite the
fact that there were more patients undergoing PCI of CTOs (p< 0.001) and LMCA
(p< 0.001) in patients with preserved blood flow before PCI (Table 2).
Comparing 2015 with 2016
We observed an increase in the number of patients with COPD (2.4% vs. 2.6%; p = 0.006). In
2016, there were more patients with SA (23.9% vs. 31.3%; p< 0.001) but less with STEMI
(26.3% vs. 23.3%; p = 0.009) and NSTEMI (21.3% vs. 14.6%; p< 0.001). The FA approach was
more common in 2016 (57% vs. 61.5%; p< 0.001), whereas RA was less common (25.4% vs.
22.8%; p = 0.02). In 2016, we noticed an increase in complexity of PCIs in the COPD group.
The rate of PCIs within bifurcations (3.3% vs. 9.6%; p< 0.001) and CTOs (3.3% vs. 6.1%;
p< 0.001) increased as compared to 2015. Considering the type of implanted stents, in 2016
we noted an increased percentage of DES stents (79.4% vs. 87.0%; p< 0.001) and a decrease in
BMS (8.1% vs. 2.6%; p< 0.001) and BVS stents (1.6% vs. 0.4%; p< 0.001). Radiation exposi-
tion and contrast dose also decreased significantly in 2016 compared to 2015 (p< 0.001).Con-
sidering these changes, the overall incidence of all complications in the COPD group
decreased in 2016 as compared to 2015, but without statistical significance (2.9% vs. 2.3%;
p = 0.15).
Predictors of all periprocedural complications, allergic reactions and no-
reflows
Among several independent predictors of all periprocedural complication rates estimated by
multivariate analysis in the overall group of patients undergoing PCIs, COPD was not con-
firmed to be an independent predictor (Fig 2). Using multivariate analysis, we displayed that
hypertension and preserved blood flow before PCI are predictors of lower periprocedural
complication rates, while increased age, male gender, diabetes, previous stroke, previous MI,
psoriasis, chronic kidney disease and ACS were predictors of increased periprocedural compli-
cation rates (Fig 2). We also noticed that smoking, COPD and diabetes were among the inde-
pendent negative predictors of periprocedural allergic reactions assessed by multivariate
analysis, while stroke and preserved blood flow assessed by TIMI score before PCI were
among factors increasing the probability of periprocedural allergic reactions (Fig 3). Moreover,
COPD alongside with age, stroke, MI, smoking, hypertension, chronic kidney disease and
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Fig 2. Predictors of all periprocedural complications assessed by multivariate analysis in the overall group of patients undergoing PCI. Abbreviations: CI,
confidence interval; OR, odds ratio; TIMI, thrombolysis in myocardial infarction.
https://doi.org/10.1371/journal.pone.0204257.g002
Fig 3. Predictors of allergic reactions during PCI assessed by multivariate analysis in the overall group of patients undergoing PCI. Abbreviations: CI, confidence
Interval; COPD, chronic obstructive pulmonary disease; OR, odds ratio; TIMI, thrombolysis in myocardial infarction.
https://doi.org/10.1371/journal.pone.0204257.g003
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ACSs were independent positive predictors of periprocedural no-reflows, while previous PCI
and baseline TIMI 2–3 grade flow decreased the probability of no-reflow (Fig 4).
Discussion
The main findings of the current study are that overall complication rates in patients with
COPD are higher as compared to patients without COPD. Among all periprocedural compli-
cations, the rate of cardiac arrests, MIs and no-reflows was higher in patients from the COPD
compared to the non-COPD group. Multivariate analysis did not confirm COPD as an inde-
pendent predictor of periprocedural complications in the overall group of patients undergoing
PCIs. Age, gender, diabetes, stroke, peracted MI, psoriasis, hypertension, kidney failure, ACS
and TIMI flow before PCI were among the independent predictors of periprocedural compli-
cations confirmed by multivariate analysis. The third finding of the current study is that
COPD and smoking along with diabetes were found to be a predictor of decreased periproce-
dural allergic reaction rate in patients undergoing PCI. The fourth significant finding of the
presented study is that COPD and smoking were predictors of increased no-reflows in patients
undergoing PCIs.
In the present study, the rate of periprocedural complications was comparable to the results
published by other authors [5]. While our estimations indicate that the rate of periprocedural
complications was significantly higher in the patients with rather than without COPD, the
study published by Enriquez et al. reported a different proportion [5]. They estimated the rate
of periprocedural complications in patients from the non-COPD group at 4.2%, which was
Fig 4. Predictors of no-reflow complications during PCI assessed by multivariate analysis in the overall group of patients undergoing PCI. Abbreviations: CI,
Confidence Interval; COPD, chronic obstructive pulmonary diseases; OR, odds ratio; PCI, percutaneous coronary intervention; TIMI, thrombolysis in myocardial
infarction.
https://doi.org/10.1371/journal.pone.0204257.g004
COPD and periprocedural complications in patients treated with PCI
PLOS ONE | https://doi.org/10.1371/journal.pone.0204257 October 1, 2018 10 / 14
significantly higher compared to the COPD group (2.6%; p = 0.004). In previously published
studies, in-hospital mortality rate in the overall population ranges between 2.2%-2.83% and
was significantly higher compared to those patients from the non-COPD groups [5,11]. Those
death rates were higher compared to our results. However, we included only periprocedural
deaths. Our analysis did not cover all hospital stays, which significantly underestimates the
death rate. Previously published studies revealed higher rates of deaths in patients with COPD
in the overall group of patients undergoing PCI and in patients with acute MI [5,12]. However,
the study published by Sung et al. revealed a lower rate of in-hospital deaths in patients with
COPD and STEMI undergoing primary PCI compared to non-COPD individuals. Further-
more they noticed an increased rate of recurrent MIs in the COPD group as compared to the
non-COPD group (4.8% vs. 1.3%; p = 0.01) [13]. Although, their population of patients
included more patients with MVD (59.7% vs. 34.4%) and baseline blood flow expressed as
TIMI grade was 0–1 before PCI (80.6% vs. 30.3%) [13].
In the current study, we revealed a higher rate of periprocedural CAs, MIs and no-reflows
in patients from the COPD group. The study published by Zhang et al. demonstrated an
increased rate of in-hospital MIs in patients with rather than without COPD (16.3% vs. 4.6%)
[14]. The study was conducted among a group of 2,362 patients undergoing PCI. Among
them, 233 (9.8%) of patients were diagnosed with COPD. Since the cardiac mortality rate was
zero in both groups, no differences were found between them. The important fact is that the
authors did not mention any information about the distribution of CAD clinical presentation
before PCI or the type of coronary atherosclerosis. Nevertheless, they also showed that the inci-
dence of heart failure was greater in the COPD group as compared to the non-COPD group
(22% vs. 9.2%) [14]. The increased rate of periprocedural MIs in patients with COPD as com-
pared to the non-COPD group could be explained by more complex and disseminated coro-
nary atherosclerosis as well as the difference in clinical presentation resulting from it. Whereas
the increased rate of no-reflows and CAs could undoubtedly be related to the prothrombotic
state attributed to COPD patients and the impeded return of blood flow through the vessel in
STEMI patients related to it [15,16]. Our study confirmed that STEMI patients had a high rate
of no-reflows (2.8%), CAs (2.6%), and the overall periprocedural complication rate was also
high (6.2%) compared to other clinical presentations of CAD. Moreover, the relationship
between no-reflows and the COPD as a prothrombotic state have been more widely discussed
in two previously published manuscripts [17,18]. Furthermore, according to our knowledge,
this is the first study verifying that among several confirmed predictors, smoking and COPD
are independent risk factors of a higher incidence of no-reflows in patients undergoing PCI.
In contrast to our results, research conducted by other authors revealed that patients with
COPD were more likely to experience major entry site complications than patients without
COPD [16,19]. The leading entry site periprocedural complication was higher rate of bleeding
that required transfusion in COPD patients. The study published by Enriquez et al. revealed
that the rate of periprocedural access site bleeding requiring transfusion in patients with
COPD was estimated at 2.3%, while in patients without COPD, it was at 1.4% (p = 0.03) [5].
We noted that puncture site bleeding rate was higher in patients with COPD compared to
non-COPD patients but without statistical significance (0.2% vs. 0.15; p = 0.06). It was attrib-
uted mainly to age, gender and therapy implementing warfarin [16,19]. However, most studies
maintain the thesis that the etiology of increased risk of periprocedural entry side bleeding is
multifactorial [5].
Another worthy finding of the current study is that the rate of allergic reactions was higher
in the COPD group as compared to the non-COPD group. Similarly, Mukherjee et al.
observed a lower incidence of COPD in patients with respiratory allergy [20]. They noticed
that among 550 participants, 18.9% of patients from the non-allergic population suffered from
COPD and periprocedural complications in patients treated with PCI
PLOS ONE | https://doi.org/10.1371/journal.pone.0204257 October 1, 2018 11 / 14
COPD, while 7.7% of allergic subjects had COPD [20]. Based on this, it could be concluded
that patients with COPD and smokers present restrained allergic reactions. According to our
knowledge, the present study is the first study which demonstrates that COPD and smoking
are independent predictors of decreased periprocedural allergic reaction rate in the overall
group of patients undergoing PCIs.
Limitations
The ORPKI database does not specifically define particular periprocedural complications and
is based on the operators’ discretion. Similar concerns could be applied to periprocedural com-
plications and their definitions usually remain in the hands of operators. Additionally, assign-
ment to the COPD and non-COPD groups was based on previous diagnosis and/or typical
treatment while no data on spirometry test results were collected. This could bring some false
positive or false negative diagnosis of COPD and bias related to this issue. However this is a
typical problem for the national registry. From the other side it presents the real life and the
real frequency of COPD diagnosis confirmed in spirometry is close to the presented in the
study. Patients with exacerbated COPD at admission could be treated in some cases with sys-
temic glucocorticoids, which might modify the extent and frequency of procedural-related
allergic reactions.
Conclusions
In the patients undergoing PCI, the periprocedural complication rate is higher in those from
the COPD group than the non-COPD group. Cardiac arrests, myocardial infarctions and no-
reflows may be found among the periprocedural complications with the largest contribution.
COPD was not an independent predictor of periprocedural complications in the overall group
of patients undergoing PCI, while COPD and smoking were found to be independent predic-
tors of decreased allergic reaction periprocedural rate and increased rate of periprocedural no-
reflows.
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